干扰素联合肝动脉栓塞化疗预防肝细胞癌根治性切除术后复发的初步观察

Preliminary study on the role of Roferon A (Interferon α-2a) combined with postoperative arterial chemoembolization in the prevention of recurrence after curative resection for human hepatocellular carcinoma.

目的 探讨干扰素联合肝动脉栓塞化疗预防肝细胞癌根治性切除术后复发的临床价值。方法 10例肝细胞癌患者于根治性切除术后2～8周经肝动脉导管行栓塞化疗。化疗后皮下注射重组α干扰素2a(罗扰素),第1～4周自100万单位渐增至450万单位维持12周。每周3次,4～6周后重复栓塞化疗一次。结果 9例患者随访超过1年,1例9个月,所有患者均未见肝内复发。结论 罗扰素可能有助于减少肝癌根治性切除术后肝内复发。

Objective To evaluate the role of Roferon A(interferon α 2a) combined with postoperative arterial chemoembolization in the prevention of recurrence after curative resection for HCC.Methods Postoperative arterial chemoembolization via a total implanted port system through the hepatic artery, followed by Roferon A injection subcutaneously on the next day. This was given to ten patients in 2～8 weeks after curative resection. Interferon α2a (Referon A) was given after chemoembolization as follows: the dosages were increased gradually from 1.0 MU three times weekly (t.i.w.) in the 1st week to 4.5 MU in the 4th week and maintained till 12th week. Chemoembolization was repeated 4～6 weeks after the first course of chemoembolization. Results Among these patients, nine patients had been followed up for more than 12 months and one patient followed up for nine months and no intrahepatic recurrences were found.Conclusion Roferon A may be helpful for reducing the intrahepatic recurrence after curative resection for HCC.